M6PR

Across TCGA pan-cancer cohorts, M6PR mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated M6PR data layer compared with 20 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher M6PR mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated M6PR expression acts as an unfavorable survival marker, although some lineages such as HNSC and UCEC show a favorable association.

LUAD, HNSC, and CCRCC are the cancer types where M6PR mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	II,III,IV	0.430	0.822	.001	26	view →
HNSC	DFS	Median	III,IV	0.758	0.447	.001	20	view →
CCRCC	DFS	Tertile	All	0.695	0.939	.004	7	view →
UCEC	OS	Tertile	III,IV	1.000	0.339	.042	4	view →
LSCC	OS	Tertile	All	1.000	0.944	.022	4	view →
PDAC	OS	Median	All	0.934	0.717	.028	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

M6PR–LUAD (DFS)

Open the LUAD breakdown →